PHOENIX OITB gGmbH: Pioneering Nano-Pharmaceutical Innovation 

In a significant leap towards advancing nano-pharmaceutical development, we are thrilled to introduce PHOENIX OITB gGmbH, a trailblazing company founded in November 2023 to provide much-needed support to industry, SMEs, startups and research groups developing nano-pharmaceuticals. 

PHOENIX-OITB gGmbH is a non-profit organisation with headquarters based in Germany. Founding members are MyBiotech GmbH (Germany), Nanomol Technologies (Spain), BioNanoNet Forschungsgesellschaft mbH (Austria), Luxembourg Institute of Science and Technology (Luxembourg), and Research Center Pharmaceutical Engineering GmbH (Austria). 

Breaking Down Barriers: An All-in-One Solution 

PHOENIX OITB gGmbH serves as an "all-in-one" Single Entry Point, offering a comprehensive suite of services, including manufacturing, characterization, testing, and innovation-related consulting including regulatory and business guidance to accelerate maturity of nano-pharmaceuticals and diagnostic agents. 

Facilitating Technology Transfer: A Consolidated Network 

With a sharp vision to eliminate barriers hindering nano-pharmaceutical innovation, PHOENIX ensures affordable and accessible support. The company provides a consolidated network of facilities, technologies, services, and expertise from across Europe. This encompasses all aspects of technology transfer, from characterization and in vitro testing to validation, scale-up, regulatory guidance, and GMP-compliant manufacturing. 

Nanomol Technologies: Driving Innovation Forward 

As a proud contributor to the PHOENIX OITB project and co-founder of Phoenix OITB gGmbH, Nanomol Technologies has played a pivotal role in launching PHOENIX OITB gGmbH as a new key player in the nano-pharmaceutical services landscape. Our expertise has contributed to shaping PHOENIX's success story, and we continue to be at the forefront of driving innovation in this transformative field. 

Streamlined Customer Experience: The Single-Entry Point (SEP) 

Customers contacting the PHOENIX Single Entry Point (SEP) will meet with a dedicated contact person to evaluate their needs. The customer will then be matched with relevant experts providing the desired services and obtain a comprehensive plan of services tailored to their requirements. PHOENIX's SEP portfolio is continually updated to align with evolving customer and market needs. 

Covering the Entire Spectrum: From Bench to Bedside 

The PHOENIX network covers the entire supply chain from bench to bedside, as well as every administration route including oral, IV, dermal, and more. Services are categorized within physico-chemical characterization, in vitro characterization, in vivo characterization, GMP (Good Manufacturing Practices) manufacturing, and innovation, offering a comprehensive approach to nano-pharmaceutical development. 

For a detailed exploration of PHOENIX OITB gGmbH services, stay tuned for the comprehensive description soon to be available on the website. 

Discover more about PHOENIX OITB gGmbH and join us on LinkedIn: PHOENIX SEP